CD40 antibody

Catalog No. ABIN2665994

This anti-CD40 antibody is a Rat Monoclonal antibody detecting CD40 in FACS. Suitable for Mouse.

Quick Overview for CD40 antibody (ABIN2665994)

Target: CD40

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This CD40 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: 1C10

Product Details anti-CD40 Antibody

Brand: Ultra-LEAF™

Purification: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Sterility: 0.2 μm filtered

Endotoxin Level:

Endotoxin level is <0.01 EU/μg of the protein (<0.001 ng/μg of the protein) as determined by the LAL test.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Preservative: Azide free

Handling Advice: This Ultra-LEAF™ solution contains no preservative, handle under aseptic conditions

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CD40

Target: CD40

Alternative Name: CD40

Background: CD40 is a 48 kD type I transmembrane glycoprotein, also known as Bp50. It is a member of the tumor necrosis factor receptor (TNFR) superfamily and is expressed on B cells, basal epithelial cells, macrophages, follicular dendritic cells, endothelial cells, and a subset of CD34+ hematopoietic progenitors. CD40 regulates B cell development/maturation, Ig isotype switching and, in combination with other signals such as IL-4, protects B cells from surface Ig-induced apoptosis and promotes proliferation. Interaction of CD40 with its ligand CD154 (gp39), which is expressed on activated T cells, is important in costimulation and immune regulation.

Pathways: NF-kappaB Signaling, Cellular Response to Molecule of Bacterial Origin, M Phase, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints